SKYE BIOSCIENCE INC (SKYE) Stock Income Statement
USA - NASDAQ:SKYE - US83086J2006 - Common Stock
1.51 USD
-0.01 (-0.66%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 51.87M | 36.43M | 34.89M | 12.11M | 7.85M | |||
| Research and Development | 34.21M | 18.70M | 27.03M | 6.01M | 2.93M | |||
| Selling, General, and Administrative Expenses | 17.66M | 17.73M | 7.85M | 6.09M | 4.92M | |||
| Operating Income | -51.87M | -36.43M | -34.89M | -12.11M | -7.85M | |||
| Interest Income/Expense | 2.97M | 2.28M | -806.30K | -710.00K | -790.00K | |||
| Other Income/Expense | null | 0 | -1.38M | null | null | |||
| Non Recurring Items | null | 6.23M | -257.50K | -6.66M | 120.00K | |||
| Income Before Taxes | -42.37M | -26.56M | -37.64M | -19.47M | -8.52M | |||
| Income Tax | 5.40K | 10.10K | 3.60K | 10.00K | 0 | |||
| Net Income | -42.37M | -26.57M | -37.64M | -19.48M | -8.52M | |||
| EBITDA | -51.27M | -36.13M | -34.76M | -11.99M | -7.82M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.0685 | -0.7281 | -5.3732 | -8.77 | -5.24 | |||
| Non GAAP EPS | -3.31 | -0.72 | null | null | null | |||
| Statistics | ||||||||
All data in USD